Satyavan Dhavale

Title: **Satyavan Dhavale: Innovator in Pharmaceutical Composition**

Introduction

Satyavan Dhavale, an accomplished inventor based in Ahmedabad, India, has made significant contributions to the field of pharmaceuticals. With two patents to his name, his innovative work focuses on improving medication delivery systems, particularly for the antipsychotic drug Clozapine.

Latest Patents

Dhavale's latest patents revolve around the development of stable extended-release pharmaceutical compositions of Clozapine. The first patent details formulations that exhibit enhanced stability under various conditions, along with the methods for preparing these compositions. His second patent describes an extended-release pharmaceutical composition that allows for a once-daily dosing regimen. This method not only helps achieve desired plasma concentrations comparable to the immediate release form but also improves patient compliance and minimizes side effects. Notably, this formulation shows no significant food effect upon oral administration, making it a practical option for patients.

Career Highlights

Currently, Satyavan Dhavale is associated with Intas Pharmaceuticals Limited, a leading player in the pharmaceutical sector. His work in this esteemed company highlights his commitment to advancing drug formulations and ensuring the safety and efficacy of patient treatments.

Collaborations

Throughout his career, Dhavale has collaborated with notable coworkers such as Rikin Patel and Kavan Pandya. These collaborations have fostered a creative environment where innovative ideas can thrive and lead to substantial advancements in pharmaceutical sciences.

Conclusion

Satyavan Dhavale's contributions to the pharmaceutical industry exemplify the impact of innovation in improving patient outcomes. His patents on Clozapine formulations reflect a dedication to enhancing medication delivery systems and patient care, marking him as a notable inventor in the realm of pharmaceuticals. As he continues to work at Intas Pharmaceuticals Limited, his future endeavors promise to bring even more groundbreaking advancements to the field.